The first case of drug-induced pseudoscleroderma and eczema craquelé related to nab-paclitaxel pancreatic adenocarcinoma treatment
نویسندگان
چکیده
Address for correspondence: Berenika Olszewska MD, Department of Dermatology, Venereology and Allergology, Medical University of Gdansk, 7 Dębinki St, 80-952 Gdansk, Poland, phone: +48 664 169 111, e-mail: [email protected] Received: 15.09.2016, accepted: 21.12.2016. The first case of drug-induced pseudoscleroderma and eczema craquelé related to nab-paclitaxel pancreatic adenocarcinoma treatment
منابع مشابه
A Near-Complete Response to Treatment with Gemcitabine plus nab®-Paclitaxel in a Patient with Metastatic Pancreatic Cancer and Poor Performance Status: A Case Report
Patients with metastatic pancreatic adenocarcinoma and poor performance status (PS) are typically excluded from clinical trials of new systemic treatments. Due to concerns that such patients cannot tolerate the greater toxicity sometimes associated with combination chemotherapy regimens, the recommended treatment for pancreatic cancer patients with poor PS is gemcitabine monotherapy. We report ...
متن کاملTreatment of metastatic pancreatic adenocarcinoma: a review.
Gemcitabine monotherapy has been the standard of care for patients with metastatic pancreatic cancer for several decades. Despite recent advances in various chemotherapeutic regimens and in the development of targeted therapies, metastatic pancreatic cancer remains highly resistant to chemotherapy. Previous studies of several combination regimens showed minimal or no significant change in overa...
متن کاملSevere hyponatremia caused by nab-paclitaxel-induced syndrome of inappropriate antidiuretic hormone secretion
Incidence of pancreatic ductal adenocarcinoma (PDAC) is increasing. Most patients have advanced disease at diagnosis and therapeutic options in this setting are limited. Gemcitabine plus nab-paclitaxel regimen was demonstrated to increase survival compared with gemcitabine monotherapy and is therefore indicated as first-line therapy in patients with metastatic PDAC and performance status Easter...
متن کاملNab-paclitaxel monotherapy in refractory pancreatic adenocarcinoma.
BACKGROUND The standard of care in patients with metastatic pancreatic adenocarcinoma is undefined beyond second line of treatment. There have been scant reports of benefit from nab-paclitaxel in patients with refractory pancreatic cancer. MATERIALS AND METHODS A retrospective review was carried out in patients with pancreatic adenocarcinoma at Siteman Cancer Center, who had received nab-pacl...
متن کاملUpdates on first-line therapy for metastatic pancreatic adenocarcinoma.
Pancreatic adenocarcinoma is the 10th most common malignancy in the United States but is responsible for the 4th most cancer related deaths. This disease can only be potentially cured through early discovery and complete surgical resection. Unfortunately, nearly half of patients have metastatic spread at presentation. Combination chemotherapy with FOLFIRINOX or gemcitabine with nab-paclitaxel c...
متن کامل